Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JOHN VICTOR HEYMACH and DON LYNN GIBBONS.
JOHN VICTOR HEYMACH
Connection Strength
7.371
DON LYNN GIBBONS
  1. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC. Clin Cancer Res. 2023 12 01; 29(23):4958-4972.
    View in: PubMed
    Score: 0.244
  2. IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC. Clin Cancer Res. 2023 04 03; 29(7):1292-1304.
    View in: PubMed
    Score: 0.233
  3. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 2023 02 13; 41(2):340-355.e6.
    View in: PubMed
    Score: 0.230
  4. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 2022 07 11; 40(7):754-767.e6.
    View in: PubMed
    Score: 0.221
  5. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol. 2022 03 01; 40(7):702-709.
    View in: PubMed
    Score: 0.209
  6. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol. 2021 08; 5.
    View in: PubMed
    Score: 0.207
  7. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.207
  8. Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. J Thorac Oncol. 2021 04; 16(4):601-609.
    View in: PubMed
    Score: 0.199
  9. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol. 2021 04; 16(4):583-600.
    View in: PubMed
    Score: 0.199
  10. Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2021 03; 14(3):313-324.
    View in: PubMed
    Score: 0.198
  11. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol. 2021 01; 16(1):127-139.
    View in: PubMed
    Score: 0.196
  12. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci Transl Med. 2020 09 02; 12(559).
    View in: PubMed
    Score: 0.194
  13. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536.
    View in: PubMed
    Score: 0.188
  14. Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. Clin Lung Cancer. 2020 07; 21(4):384-388.
    View in: PubMed
    Score: 0.188
  15. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 06 20; 37(18):1558-1565.
    View in: PubMed
    Score: 0.177
  16. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov. 2018 09; 8(9):1156-1175.
    View in: PubMed
    Score: 0.168
  17. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682.
    View in: PubMed
    Score: 0.149
  18. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res. 2016 07 15; 22(14):3630-42.
    View in: PubMed
    Score: 0.142
  19. The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression. Oncoimmunology. 2015 May; 4(5):e1002731.
    View in: PubMed
    Score: 0.132
  20. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun. 2024 Apr 11; 15(1):3152.
    View in: PubMed
    Score: 0.062
  21. Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features. Front Oncol. 2024; 14:1324057.
    View in: PubMed
    Score: 0.062
  22. Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept. Cell Rep Med. 2024 Mar 19; 5(3):101463.
    View in: PubMed
    Score: 0.062
  23. Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy. Cancers (Basel). 2024 Feb 26; 16(5).
    View in: PubMed
    Score: 0.062
  24. Adapting Nanopore Sequencing Basecalling Models for Modification Detection via Incremental Learning and Anomaly Detection. bioRxiv. 2023 Dec 20.
    View in: PubMed
    Score: 0.061
  25. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic?Targets. JTO Clin Res Rep. 2024 Feb; 5(2):100623.
    View in: PubMed
    Score: 0.061
  26. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 Mar; 19(3):500-506.
    View in: PubMed
    Score: 0.061
  27. Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. Oncologist. 2023 Nov 02; 28(11):e1065-e1074.
    View in: PubMed
    Score: 0.061
  28. Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 11 01; 29(21):4408-4418.
    View in: PubMed
    Score: 0.061
  29. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2024 Apr; 167(4):1444-1453.e4.
    View in: PubMed
    Score: 0.060
  30. Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis. Cancers (Basel). 2023 Oct 01; 15(19).
    View in: PubMed
    Score: 0.060
  31. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma. Mod Pathol. 2023 Dec; 36(12):100326.
    View in: PubMed
    Score: 0.060
  32. Case Report: Immune checkpoint inhibitor-induced multiorgan vasculitis successfully treated with rituximab. Front Nephrol. 2023; 3:1168614.
    View in: PubMed
    Score: 0.059
  33. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571.
    View in: PubMed
    Score: 0.059
  34. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clin Res Rep. 2023 Aug; 4(8):100533.
    View in: PubMed
    Score: 0.059
  35. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health. 2023 Jul; 5(7):e404-e420.
    View in: PubMed
    Score: 0.059
  36. Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer. Nat Commun. 2023 04 25; 14(1):2364.
    View in: PubMed
    Score: 0.058
  37. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat Genet. 2023 05; 55(5):807-819.
    View in: PubMed
    Score: 0.058
  38. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
    View in: PubMed
    Score: 0.058
  39. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun. 2023 02 08; 14(1):695.
    View in: PubMed
    Score: 0.058
  40. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol. 2023 01; 7:e2200540.
    View in: PubMed
    Score: 0.057
  41. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer. 2022 Oct 29; 174:112-117.
    View in: PubMed
    Score: 0.056
  42. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer. 2022 10; 172:19-28.
    View in: PubMed
    Score: 0.056
  43. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers (Basel). 2022 Jul 17; 14(14).
    View in: PubMed
    Score: 0.055
  44. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform. 2022 07; 6:e2200040.
    View in: PubMed
    Score: 0.055
  45. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clin Cancer Res. 2022 06 01; 28(11):2461-2473.
    View in: PubMed
    Score: 0.055
  46. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Netw Open. 2022 06 01; 5(6):e2215589.
    View in: PubMed
    Score: 0.055
  47. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. J Exp Clin Cancer Res. 2022 May 11; 41(1):172.
    View in: PubMed
    Score: 0.055
  48. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer. 2022 02; 10(2).
    View in: PubMed
    Score: 0.054
  49. Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 05; 23(3):236-243.
    View in: PubMed
    Score: 0.054
  50. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 11; 164(5):1327-1337.
    View in: PubMed
    Score: 0.054
  51. Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer. 2022 02; 164:69-75.
    View in: PubMed
    Score: 0.053
  52. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun. 2021 12 06; 12(1):7081.
    View in: PubMed
    Score: 0.053
  53. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun. 2021 11 17; 12(1):6655.
    View in: PubMed
    Score: 0.053
  54. Deep learning-based prediction of the T cell receptor-antigen binding specificity. Nat Mach Intell. 2021 Oct; 3(10):864-875.
    View in: PubMed
    Score: 0.052
  55. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun. 2021 08 19; 12(1):5045.
    View in: PubMed
    Score: 0.052
  56. Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. J Thorac Oncol. 2021 11; 16(11):1821-1839.
    View in: PubMed
    Score: 0.052
  57. Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother. 2021 Jul; 70(7):1977-1978.
    View in: PubMed
    Score: 0.051
  58. Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. Cancer Discov. 2021 10; 11(10):2506-2523.
    View in: PubMed
    Score: 0.051
  59. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel). 2021 Mar 12; 13(6).
    View in: PubMed
    Score: 0.050
  60. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.050
  61. Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. Lung Cancer. 2021 04; 154:76-83.
    View in: PubMed
    Score: 0.050
  62. Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology. bioRxiv. 2021 Jan 28.
    View in: PubMed
    Score: 0.050
  63. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother. 2021 Jul; 70(7):1965-1976.
    View in: PubMed
    Score: 0.050
  64. KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res. 2020; 10(12):4464-4475.
    View in: PubMed
    Score: 0.049
  65. AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Mol Cancer Res. 2021 03; 19(3):485-497.
    View in: PubMed
    Score: 0.049
  66. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol. 2020 11 04; 21(1):271.
    View in: PubMed
    Score: 0.049
  67. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist. 2020 10; 25(10):e1457-e1463.
    View in: PubMed
    Score: 0.048
  68. Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer. 2020 08; 146:303-309.
    View in: PubMed
    Score: 0.048
  69. Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clin Lung Cancer. 2021 05; 22(3):e415-e424.
    View in: PubMed
    Score: 0.048
  70. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.
    View in: PubMed
    Score: 0.048
  71. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother. 2020 Aug; 69(8):1519-1534.
    View in: PubMed
    Score: 0.047
  72. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. J Immunother Cancer. 2020 04; 8(1).
    View in: PubMed
    Score: 0.047
  73. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. J Thorac Oncol. 2020 05; 15(5):777-791.
    View in: PubMed
    Score: 0.047
  74. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020 01 30; 11(1):603.
    View in: PubMed
    Score: 0.047
  75. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257.
    View in: PubMed
    Score: 0.046
  76. Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. Ann Thorac Surg. 2020 02; 109(2):358-366.
    View in: PubMed
    Score: 0.046
  77. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov. 2019 05; 9(5):646-661.
    View in: PubMed
    Score: 0.044
  78. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 06; 14(6):1021-1031.
    View in: PubMed
    Score: 0.044
  79. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer. 2018 06 06; 6(1):48.
    View in: PubMed
    Score: 0.042
  80. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. J Thorac Oncol. 2018 06; 13(6):779-791.
    View in: PubMed
    Score: 0.041
  81. Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 06; 105(6):1621-1626.
    View in: PubMed
    Score: 0.041
  82. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097.
    View in: PubMed
    Score: 0.039
  83. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res. 2017 07 15; 77(14):3870-3884.
    View in: PubMed
    Score: 0.039
  84. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget. 2017 Apr 25; 8(17):28575-28587.
    View in: PubMed
    Score: 0.039
  85. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res. 2017 04; 5(4):319-329.
    View in: PubMed
    Score: 0.038
  86. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct 20; 34(30):3638-3647.
    View in: PubMed
    Score: 0.037
  87. Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. Clin Cancer Res. 2016 Dec 15; 22(24):6278-6289.
    View in: PubMed
    Score: 0.036
  88. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1674-1686.
    View in: PubMed
    Score: 0.035
  89. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res. 2016 Feb 01; 22(3):609-20.
    View in: PubMed
    Score: 0.035
  90. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014 Oct 28; 5:5241.
    View in: PubMed
    Score: 0.032
  91. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov. 2013 Aug; 3(8):870-9.
    View in: PubMed
    Score: 0.029
  92. miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res. 2011 Jan; 9(1):25-35.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.